Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib, Lenalidomide, Dexamethasone vs Lenalidomide After Stem-cell Transplant for Multiple Myeloma
NCT02659293Phase 3Active, not recruiting
- Sponsor
- University of Chicago
- Start
- Apr 2016
- Primary completion
- Nov 2027
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 2
01
Overview
A Phase 3 trial of carfilzomib in multiple myeloma (MM), sponsored by University of Chicago. Started Apr 2016; status: active, not recruiting.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02659293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659293.